INBX
Inhibrx Biosciences Inc.
$106.85
+$5.53(+5.46%)
52
Overall
40
Value
63
Tech
55
Quality
Market Cap
$1.17B
Volume
228.81K
52W Range
$12.68 - $155.29
Target Price
$277.50
Order:
Income Statement
| Metric | Trend | Chart | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|
| REVENUE | |||||
| Total Revenue | $1.8M | $200.0K | $1.3M | ||
| Total Revenue | $1.8M | $200.0K | $1.3M | ||
| GROSS PROFIT | |||||
| Gross Profit | $1.8M | $200.0K | $1.3M | ||
| OPERATING EXPENSES | |||||
| Operating Expenses | $220.4M | $331.6M | $136.3M | ||
| Research & Development | $191.6M | $203.7M | $113.0M | ||
| Research Expense | $191.6M | $203.7M | $113.0M | ||
| Selling, General & Administrative | $29.4M | $127.9M | $23.3M | ||
| General & Administrative Expenses | $29.4M | $127.9M | $23.3M | ||
| Other Operating Expenses | $-580.0K | -- | -- | ||
| OPERATING INCOME | |||||
| Operating income | $-218.6M | $-331.4M | $-135.0M | ||
| EBITDA | $-205.5M | $1.7B | $-122.9M | ||
| NON-OPERATING ITEMS | |||||
| Interest Expense (Non-Operating) | $31.8M | $13.5M | $12.2M | ||
| Intinc | $11.9M | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-19.9M | $-13.5M | $-12.2M | ||
| Other Income/Expense | -- | $-2.0B | $381.0K | ||
| Other Special Charges | -- | $2.0B | $-381.0K | ||
| PRE-TAX INCOME | |||||
| EBIT | $-206.7M | $1.7B | $-127.9M | ||
| Pre-Tax Income | $-238.6M | $1.7B | $-140.1M | ||
| INCOME TAX | |||||
| Tax Provision | $1.6M | $2.0K | $2.0K | ||
| NET INCOME | |||||
| Net Income | $-240.2M | $1.7B | $-140.1M | ||
| Net Income (Continuing Operations) | $-240.2M | $1.7B | $-140.1M | ||
| Net Income (Discontinued Operations) | $-240.2M | $1.7B | $-140.1M | ||
| Net Income (Common Stockholders) | $-240.2M | $1.7B | $-140.1M | ||
| Normalized Income | $-175.3M | $1.7B | $-138.7M | ||
| TOTALS | |||||
| Total Expenses | $220.4M | $331.6M | $136.3M | ||
| SHARE & EPS DATA | |||||
| Average Shares Outstanding | $11.8M | $14.8M | $15.5M | ||
| Average Shares Outstanding (Diluted) | $11.8M | $15.0M | $15.5M | ||
| Shares Outstanding | $14.7M | $14.5M | $14.7M | ||
| Basic EPS | $-20.48 | $114.01 | $-9.04 | ||
| Basic EPS (Continuing Operations) | $-20.48 | $114.01 | $-9.04 | ||
| Diluted EPS | $-20.48 | $112.62 | $-9.04 | ||
| Diluted EPS (Continuing Operations) | $-20.48 | $112.62 | $-9.04 | ||
| OTHER METRICS | |||||
| Other Gand A | $29.4M | $127.9M | $23.3M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | INBX | $106.85 | +5.5% | 228.81K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Inhibrx Biosciences Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW